A trial of an oral pill aimed at preventing HIV infection in African women has been halted due to poor results, the trial operator Family Health International announced this week.
The US Centers for Disease Control described the results as “disappointing,” and the trial’s monitoring committee had decided to stop the trial as it “could not demonstrate efficacy even if it continued to its originally planned conclusion.”
The same oral treatment, known as pre-exposure prophylaxis (PrEP) for HIV prevention, has been shown to reduce risk of HIV transmission among men who have sex with men by between 73 and 90 percent.
Read the article in the Times Live.
Read the original statement from the Family Health International
Be part of our network of leaders and innovators.Join now